Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT06200714

A Study Based on Medical Records in Spain That Looks at Diarrhoea Control in People With Pulmonary Fibrosis Who Are Taking Nintedanib

Sponsor: Boehringer Ingelheim

View on ClinicalTrials.gov

Summary

This is an observational, non-interventional, and prospective post authorization safety study (PASS) that will describe the real-world proportion of patients that achieve nintedanib-associated diarrhoea control after 12 weeks of follow-up, in hospital settings in Spain. It will include outpatients (i.e., those attending ambulatory visits) with interstitial lung diseases (IPF) and other progressive pulmonary fibrosis (PPF) treated with nintedanib (150 mg bid) and having a first episode of diarrhoea after nintedanib initiation.

Official title: Observational, Multicentre, Prospective, Real-world Post-authorization Safety Study Describing the Achievement of Nintedanib-associated DIArrhoea Control After 12 Weeks of Follow-up in Patients With Idiopathic puLmonary FIBrosis (IPF) and Progressive Pulmonary Fibrosis (Other Than IPF) in Spain: the DIALFIB Study

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

18

Start Date

2024-07-16

Completion Date

2025-04-29

Last Updated

2026-05-13

Healthy Volunteers

No

Interventions

DRUG

Nintedanib

Participants received 150 milligrams (mg) Nintedanib, twice daily.

Locations (8)

Hospital Clínic i Provincial de Barcelona

Barcelona, Spain

Hospital Universitari Germans Trias i Pujol

Barcelona, Spain

Hospital Universitario de Cruces

Bizkaia, Spain

Hospital Universitario Virgen de las Nieves

Granada, Spain

Hospital de La Princesa

Madrid, Spain

Hospital Clínico San Carlos

Madrid, Spain

Hospital Álvaro Cunqueiro

Pontevedra, Spain

Hospital Clínico Universitario de Valencia

Valencia, Spain